US/UK/Canada

Share

About Us

ISR is an innovation-driven pharmaceutical research company in the field of immunotherapy. The company’s focus is on clinical and preclinical research with the goal of developing a broad-spectrum, antiviral therapy platform for immunomodulating drugs. www.israb.se Mangold Fondkommission is the company’s Certified Adviser and can be reached at +46 8 503 01 550.

Contacts

  • IR contact
    +46 73 308 00 34

    • Quotes

    The discoveries by Dr Allison and Dr Honjo are ground breaking for our understanding of the T-cell activation and regulation, findings which now have lead to the development of new treatment principles. For ISR this is a confirmation that we’re working in the very field, which this year is rewarded by the Nobel Prize. Tremendously stimulating!
    Ola Winqvist, CEO ISR
    We are excited to have started enrolment of patients. The study is unique, where ISR048s capacity to eradicate HIV virus carrying cells will be evaluated
    Ola Winqvist, CEO of ISR
    Pick a time period -
    Tags ( Active)

    The ISR Immunolide Platform Expanded into Hepatitis B

    Screenings of the substances from ISR’s Immunolide platform have identified a new pharmaceutical lead candidate, ISR051, which has immune stimulating effects, apparently advantageous in the treatment of hepatitis B. ISR now plans to expand its research and development portfolio to encompass, apart from HIV, tuberculosis and cancer, also hepatitis B.The hepatitis B virus (HBV) is one of the world’s most ubiquitous diseases, where WHO estimates over two billion people have or have had the disease and 240 million are chronic bearers. Nearly 700,000 people die in this disease every year, and 25%

    Activation of the Immune Defence in the Nobel Prize Focus

    The 2018 Nobel Prize in Physiology or Medicine awarded jointly to Dr. James P. Allison and Dr. Tasuku Honjo, highlights the significance of the immune system research. ISR is a company developing new immune stimulating pharmaceutical treatments of HIV, tuberculosis and cancer, with the help of the immune system.Our lead substance ISR048 stimulates two of the three pathways leading to T-cell activation, which can be further amplified and extended by adding pharmaceuticals inhibiting CTLA-4 and PD-1 (i.e. Checkpoint Blockage), the subjects of this year’s Nobel Prize. A phase II clinical trial

    First patient included into ISR’s Phase IIa HIV study

    As previously announced, ISR has a Phase IIa study of HIV-infected patients on anti-retroviral therapy (ART), where patients will be randomized to receive GnRH agonist (ISR048) in addition to ART, or ART alone. The first patient is now enrolled.ISR’s Phase IIa clinical study, ISR-003, is conducted at the Karolinska University Hospital Huddinge and at the South Hospital in Stockholm, SÖS. The study is composed of two arms with a total of 26+26 patients to be randomized into ART+ISR048 or to ART alone in the control group. Patients will be treated for 3 months and then followed for an

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe